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Multiple myeloma is the second most common hematologic malignancy. It accounts for 20,580 new cancer cases in the USA in
2009, including 11,680 cases in men, 8,900 cases in women, and 10,580 deaths overall. Although the disease remains still incurable,
outcomes have improved substantially over recent years thanks to the use of high-dose therapy and the availability of novel agents,
such as the immunomodulatory drugs thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. Various trials
have shown the advantages linked to the use of novel agents in the transplant and not-transplant settings. In particular, this paper
will present an overview of the results achieved with lenalidomide-containing combinations in patients eligible for high-dose
therapies, namely, young patients. The advantages obtained should always be outweighed with the toxicity profile associated with
the regimen used. Therefore, here, we will also provide a description of the main adverse events associated with lenalidomide and
its combination.
1. Introduction
For many years, the combination vincristine-doxorubicin-
dexamethasone (VAD) was the standard induction treatment
for young patients with multiple myeloma (MM) eligible for
autologous stem cell transplantation (ASCT). Ten years ago
patients candidate for transplant used to receive VAD for 4–6
cycles before undergoing transplantation, leading to a partial
response (PR) rate ranging from 52% to 63%, with 3% to
13% of complete response (CR) rate. The availability of new
drugs, such as thalidomide, lenalidomide, and bortezomib,
has dramatically changed the treatment paradigm of this dis-
ease and significantly increased the therapeutic options [1].
Lenalidomide is an immunomodulatory drug with
higher potency than its analogue thalidomide and without
sedative or neurotoxic adverse effects. Differences between
lenalidomide and thalidomide activity have been shown
in preclinical studies. In comparison with thalidomide,
lenalidomide has more antiproliferative activity against
hematopoietic tumors, including myeloma cell lines and
patients’ cells [2, 3], increased inhibition of tumor necrosis
factor secretion from activated monocytes, and increased
activation of T cells and natural killer cells [4]. In contrast,
thalidomide has more antiangiogenic activity than lenalido-
mide in human models. Both lenalidomide and thalidomide
interfere with key events in the angiogenic process, and
activities of these drugs can be differentiated qualitatively
depending on what component is studied [5]. Lenalidomide
is administered orally, and the most common toxicities
related to its therapy are neutropenia, thrombocytopenia,
and thrombosis [6].
On the basis of two phase 3 clinical trials, lenalidomide
has already shown additive and/or synergistic effects when
used in association with dexamethasone [7–9]; therefore,
this combination is at present indicated for patients with
MM, who have received at least one previous therapy.
[10, 11]. New and ongoing trials are assessing the benefit
of lenalidomide-combination therapies in early phase of
treatment. In particular, the present paper will provide
an overview of the main latest combinations including
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lenalidomide, used in young patients either as induction or
maintenance treatment.
2. Induction Regimens Including Lenalidomide
2.1. Standard Approaches. Lenalidomide has been tested in
various clinical trials as induction regimen before ASCT.
In one randomized trial, lenalidomide in combination with
high-dose dexamethasone (RD) showed to be superior to
dexamethasone alone [12]. In that study, patients assigned
to RD received lenalidomide at the dose of 25mg/day for
28 days and dexamethasone at the dose of 40mg/day on
days 1–4, 9–12, 17–20, for three 35-day induction cycles.
The same dexamethasone dose was administered in the other
treatment arm. Patients assigned to treatment with RD had
at least PR of 78%, with very good PR (VGPR) of 63%,
while the respective figures for dexamethasone alone were
48% and 16% (P < 0.001). The 1-year progression-free
survival (PFS) was higher with RD (78% versus 52%; P =
0.002), so was the 1-year overall survival (OS) (94% versus
88%, P = 0.25). Toxicities were higher with RD and were
grade 3-4 neutropenia (21% versus 5%; P < 0.001), and
thromboembolism despite aspirin prophylaxis (24% versus
5%; P < 0.001). Considering the good efficacy of the two-
drug regimen, 40 eligible patients crossed over to RD arm.
The efficacy of this combination was further improved
by reducing the dose of dexamethasone. A phase 3 trial
also demonstrated superior survival and lower toxicity with
lenalidomide plus low-dose dexamethasone (Rd) [13]. In
that trial, patients who were randomly assigned to be treated
with RD received lenalidomide at the dose of 25mg on days
1–21 plus dexamethasone 40mg on days 1–4, 9–12, and 17–
20 of a 28-day cycle, while subjects in the Rd arm received
the same dose of lenalidomide and dexamethasone at 40mg
on days 1, 8, 15, and 22 of a 28-day cycle. At least PR rate
was 81% in the RD arm and 70% in the Rd arm (P =
0.009), with a CR of 5% and 4%, respectively. OS was lower
with RD than Rd (2-year OS was 75% versus 87%, resp.).
Toxicities were significantly higher with RD compared to
Rd, in particular deep-vein thrombosis (DVT) or pulmonary
embolism (26% versus 12%; P < 0.001), and infections
(16% versus 9%; P = 0.04). Considering its good toxicity
profile, almost all recent trials have used the lower-dose of
dexamethasone (namely, 40mg once weekly or equivalent)
and high-dose dexamethasone is no longer recommended in
newly diagnosed MM.
The role of Rd induction was also assessed in an Italian
study [14]. Four-hundred two patients with newly diagnosed
MM were included in the study. Patients received induction
therapy with four 28-day cycles of Rd. Patients were subse-
quently randomized to receive treatment with melphalan-
prednisone-lenalidomide (MPR) or high-dose melphalan
(MEL200) followed by transplantation. On an intention to
treat basis, best responses after Rd induction were 87% PR
rate, 52% VGPR rate, and 13% CR. Induction with Rd was
well tolerated: the most frequent grade 3-4 adverse events
were neutropenia (8%), anemia (7%), infections (4%), and
skin rash (5%). The incidence of thromboembolic events
was similar in patients randomized to aspirin (2%) or low-
molecular-weight heparin (1%) as thromboprophylaxis (P =
0.45). These results further confirm the positive role of Rd as
induction regimen.
2.2. New Approaches. Based on the promising results
obtained with lenalidomide in combination with dexam-
ethasone, new combinations including lenalidomide have
been tested to further improve outcomes and to achieve
maximal tumour reduction.
A case-matched study compared clarithromycin-
lenalidomide plus low-dose dexamethasone (BiRd) with Rd
as initial therapy for newly diagnosed MM patients [15].
Seventy-two patients treated with either BiRd or Rd were
included in this retrospective analysis. On intention-to-treat,
CR rate was significantly higher with BiRd compared with
Rd (46% versus 14%, resp.; P < 0.001) and so was also
VGPR rate or better (74% versus 33%, resp.; P < 0.001).
BiRd also led to longer median PFS, 48 months with BiRd
compared to 28 months with Rd (P = 0.044). The 3-year
OS was also improved in patients receiving BiRd (90%
versus 73%; P = 0.17). Main grade 3-4 toxicities of BiRd
were hematologic, in particular thrombocytopenia (24%
versus 8%; P = 0.012). Higher rates of infections (10%
versus 17%; P = 0.218) and dermatological toxicity (4%
versus 13%; P = 0.129) were reported with Rd. These results
demonstrate the marked benefits of adding clarithromycin
to Rd. Future phase 3 trials are needed to confirm and
validate these findings.
Richardson and colleagues evaluated the role of
bortezomib-lenalidomide-dexamethasone (VRD) in a phase
1-2 study including 66 patients with MM [16]. Bortezomib
was administered at the dose of 1.0 or 1.3mg/m2 on days
1, 4, 8, 11; lenalidomide at 15 to 25mg on days 1–14;
dexamethasone at 40 or 20mg on days 1, 2, 4, 5, 8, 9, 11, 12.
In the phase 2 study, bortezomib was given at 1.3mg/m2,
lenalidomide 25mg, and dexamethasone 20mg. PR rate was
100% in both the phase 2 population and overall, with 74%
and 67% each achieving at least VGPR. Forty-two percent
of patients proceeded to transplantation. With a median
followup of 21 months, estimated 18-month PFS and OS
for the combination treatment with/without transplantation
were 75% and 97%, respectively. Most common toxicities
included sensory neuropathy (80%) and fatigue (64%),
with only 27%/2% and 32%/3% grade 2/3, respectively.
Moreover, 32% reported neuropathic pain (11%/3%, grade
2/3). Grade 3-4 hematologic toxicities included lymphopenia
(14%), neutropenia (9%), and thrombocytopenia (6%).
Thrombosis was rare (6%), and no treatment-related
mortality was reported. In the light of these results, VRD
proved to be effective and well tolerated in newly diagnosed
MM.
The role of VRD was also confirmed in a French phase
2 trial [17]. Thirty-one patients younger than 65 years
with newly diagnosed MM were enrolled and received VRD
induction treatment (bortezomib 1.3mg/m2 (days 1, 4, 8,
11), lenalidomide 25mg (days 1–14), and oral dexametha-
sone 40mg (days 1, 8 and 14)). Patients underwent ASCT
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and subsequently received VRD consolidation and lenalido-
mide maintenance. All patients could be evaluated for
response after induction: at least PR was 97%, with a VGPR
rate of 26%. Overall, the most common adverse events were
sensory peripheral neuropathy (45%), only grade 1-2 events
were detected, and gastrointestinal events (42%). Grade 3-
4 hematologic toxicities included neutropenia (26%) and
thrombocytopenia (6%). No treatment-related deaths were
reported. All patients received aspirin, and no DVT nor
pulmonary embolism was detected.
Lenalidomide associated with adriamycin and dexam-
ethasone (RAD; lenalidomide 25mg days 1–21; infusional
adriamycin 9mg/m2 per day on days 1–4; dexamethasone
40mg days 1–4 and 17–20) was assessed in another phase
2 study [18]. Seventy-five patients with a median age of
57 (range, 35–66) years have been enrolled. In a prelimi-
nary analysis, 17 patients were evaluated for postinduction
response. Ten subjects (59%) achieved VGPR or better: 6
patients had VGPR and 2 patients each CR and stringent CR.
Fifty-one patients were evaluated for toxicity during RAD
induction: 31% experienced a serious adverse event, of which
68% were treatment related. Most frequent events were
venous thrombosis (n = 4), pyrexia (n = 3), and syncope
(n = 2). Neutropenia, extravasation, pleural effusion, and
allergic dermatitis accounted for one serious adverse event
each. These preliminary results suggest that RAD is a well-
tolerated and effective novel induction upfront approach for
MM. Incidence of venous thromboembolism was acceptable,
while no neurotoxicity was reported.
A more intense combination including four drugs
has been recently tested. Promising results were achieved
in a phase 2 multicenter study comparing bortezomib-
dexamethasone-cyclophosphamide plus lenalidomide
(VDCR) with VDR, bortezomib-cyclophosphamide-
dexamethasone (VDC), and VDC modified (VDC-
mod) [19]. In all arms, the doses of bortezomib and
dexamethasone were as follow: bortezomib 1.3mg/m2 on
days 1, 4, 8, 11; dexamethasone 40mg on days 1, 8, 15.
In the VDCR, lenalidomide was given at 15mg on days
1–14 and cyclophosphamide at 500mg/m2 days 1, 8; in
the VDC-mod, arm cyclophosphamide was also given on
day 15; in the VDR arm, lenalidomide was administered
at 25mg on days 1–14. The four induction regimens were
followed by four 42-day maintenance cycles of bortezomib
1.3mg/m2 on days 1, 8, 15, 22. A total of 41 patients were
assigned to VDCR arm, and responses were promising, with
at least PR of 88% and 24% of CR, and were comparable
with the responses detected in the other arms. The toxicity
profile associated with VDCR was slightly higher, with
serious adverse events detected in 42% of patients, resulting
in treatment discontinuation in 19% of the subjects. In
particular, the incidence of grade ≥ 3 peripheral neuropathy
was 13%, grade ≥ 3 neutropenia was 42%, and grade ≥
3 thrombocytopenia was seen in 10% of VDCR patients.
These results show that VDCR is an effective treatment
option, but it is not significantly superior to other less toxic
combinations, such as VRD.
A phase 1-2 study evaluated the combination VRD plus
pegylated liposomal doxorubicin (VRDD) [20]. Patients
received lenalidomide at 15–25mg on days 1–14, bortezomib
1.3mg/m2 on days 1, 4, 8, 11, dexamethasone 20/10mg
(cycles 1–4/5–8; days of and after bortezomib), doxorubicin
20 or 30mg/m2 (day 4) at 4 dose levels for up to eight
21-day cycles. Response rates in 57 patients who could be
evaluated for response were as follows: 96% at least PR,
58% at least VGPR, and 30% CR/near CR. Patients treated
at the maximum tolerated dose, which was determined as
lenalidomide 25mg, bortezomib 1.3mg/m2, dexamethasone
20mg, and doxorubicin 30mg/m2, and completed at least 4
cycles, showed 100% of at least PR. Overall, toxicities were
manageable, with grade 3-4 toxicities including neutropenia
(18%), thrombocytopenia (7%), infections (16%), and DVT
(2%). Grade 3 peripheral neuropathy was detected in 4%
of patients, while no grade 4 peripheral neuropathy nor
treatment-related deaths was reported. RVDD showed to be
well tolerated and highly active in newly diagnosed MM.
The incidence of both venous and arterial thrombosis
in newly diagnosed patients increases when lenalidomide
is combined with dexamethasone or chemotherapy: thus,
thromboprophylaxis is recommended for the first 6 months
of therapy. For patients with standard thromboembolic
risk, low-dose aspirin is indicated; for patients with high
thromboembolic risk, low-molecular-weight heparin is rec-
ommended [21].
3. Impact of Lenalidomide on
Stem Cell Collection
Recent reports have focused on hypothetical negative impact
of new drugs on stem cell mobilization. Particularly, hema-
tologic toxicity related to treatment with lenalidomide has
raised concerns about lenalidomide use in early phase of
treatment and on its possible negative effect on peripheral
blood stem cell (PBSC) collection in young patients under-
going ASCT.
In fact, patients mobilized with granulocyte colony-
stimulating factor (G-CSF) alone after RD induction have
collected a median yield of stem cell ranging from 3.1 to
7.9× 106 CD34+/Kg [22–26].
By contrast, the use of cyclophosphamide in addition
to G-CSF may overcome this problem and significantly
increases the yield of stem cells collected. Different retrospec-
tive published trials on lenalidomide induction have in fact
shown a median yield of PBSC ranging from 6.3 to 14.2×106
CD34+/Kg. These data support the idea that RD is probably
not a significant burden for an adequate stem cell collection,
especially if the duration of induction with RD is short [22–
26].
4. Consolidation and Maintenance Approaches
Including Lenalidomide
Consolidation and maintenance therapies have the potential
to improve the results achieved after induction treatment
and transplantation [27]. Although preliminary data showed
that lenalidomide as consolidation/maintenance therapy
after ASCT improved responses, the role of lenalidomide
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treatment as alternative to ASCT still remains uncertain, and
further studies are needed.
Consolidation treatment with MPR has been tested in
the Italian study, comparing MPR (six 28-day cycles of
melphalan (0.18mg/Kg days 1–4), prednisone (2mg/Kg days
1–4), and lenalidomide (10mg days 1–21)) versus tandem
MEL200 (melphalan 200mg/m2) with stem cell support
[14]. Response rates were similar: at least VGPR rate was
60% with MPR versus 58% with Mel200, including a CR rate
of 20% versus 25%, respectively. After a median followup
of 26 months, 2-year PFS was 54% in MPR and 73% in
MEL200 (HR = 0.51, P < 0.001) and this benefit was
maintained in the subgroup of patients with standard- or
high-risk cytogenetic features, with a 2-year PFS of 46% in
the MPR group versus 78% in the MEL200 group in patients
with standard risk (HR = 0.57, P = 0.007), and 27% for
MPR versus 71% for MEL200 in high-risk patients with
t(4; 14) or t(14; 16) or del17p abnormalities (HR = 0.32, P =
0.004). The achievement of CR prolonged PFS, and this was
more evident in the Mel200 arm. Two-year PFS in patients
who achieved CR was 66% in MPR versus 87% in Mel200
group; 2-year PFS in patients who achieved PR was 56%
versus 77%, respectively. PFS was significantly prolonged in
patients who received a double ASCT. During consolidation
therapy, the incidence of grade 3-4 neutropenia (89% versus
55%), infections (17% versus 0%) and gastrointestinal
complications (21% versus 0%), was higher in MEL200
patients (P < 0.001). This is the first report showing a
PFS advantage for ASCT in comparison with conventional
therapies including novel agents; however, longer followup is
needed to draw definitive conclusion. To date, more informa-
tion is available on the use of lenalidomide as maintenance
therapy. While maintenance including alkylating agents and
interferon showed no significant impact on OS [28, 29],
thalidomide maintenance seems to be an effective strategy
to improve survival [30–33]. However, prolonged exposure
to thalidomide may cause cumulative toxicity. Because of
its better safety profile, lenalidomide could be an optimal
alternative option to thalidomide as maintenance therapy.
In a phase 3 randomized double-blind, placebo-
controlled study (CALGB 100104), patients with non-
progressive disease after a first line ASCT were randomized
to receive placebo or lenalidomide at starting dose of 10mg
daily, escalated to 15mg daily after 3 months [34]. Final anal-
ysis showed that lenalidomide monotherapy maintenance
initiated at 100–110 days after ASCT and continued until
disease progression, considerably delays time to progression
compared with placebo (median time to progression 42.3
months in the lenalidomide maintenance arm versus 21.8
months in the placebo arm), with a good safety profile
and low discontinuation rate due to adverse events (12% in
the lenalidomide group versus 2% in the placebo group).
Furthermore, significant improvements in time to progres-
sion were observed in the group receiving lenalidomide
maintenance regardless of β2 microglobulin levels or choice
of induction therapy (thalidomide or lenalidomide).
In the IFM2005-02 study, MM patients younger than 65
years of age, with at least standard disease after a first line
ASCT, were randomly assigned to receive consolidation with
lenalidomide (25mg daily, 21 days/month, for 2 months)
followed by maintenance with placebo or lenalidomide
(10 to 15mg daily) until relapse [35]. Results showed
that lenalidomide maintenance significantly improved PFS,
with a median PFS of 42 months from randomization in
the lenalidomide group versus 24 months in the placebo
group (P < 0.01). This benefit was observed regardless of
risk factors, such as cytogenetic profile (del 13, + or −),
β2 microglobulin levels, or response after transplantation.
Preliminary data published indicated that this regimen is
well tolerated, with a discontinuation rate for serious adverse
events similar to placebo.
Of note, both the CALGB and IFM2005-02 studies
detected an improvement in PFS with lenalidomide mainte-
nance, but only the CALGB study reported also an OS benefit
with this approach [34, 35].
Recently, the higher incidence of second cancer in
patients treated with lenalidomide for long time led to
reconsidering the benefit and the duration of lenalidomide
maintenance. In both the CALGB 100104 and IFM2005-
02, the rate of second primary malignancy was 8%. An
analysis of pooled data from 2459 patients enrolled in
different studies including maintenance with lenalidomide
was performed. Not all the studies showed an increased
second cancer risk, whereas different studies confirmed
that the benefits achieved with lenalidomide maintenance
outweigh the risk to develop a second primary malignancy
[36]. Despite the results presented above, a longer period
of followup is required to draw definitive conclusion on the
role of lenalidomide as consolidation/maintenance therapy,
to better define the impact of lenalidomide maintenance on
OS and its cumulative toxicity and to establish the optimal
duration of lenalidomide maintenance therapy.
5. Conclusions
Considering its dual mechanism of action of lenalidomide,
comprising tumoricidal effects which rapidly reduce the
MM tumor burden, and its immunomodulatory effects
which enhance the immune function and maintain disease
suppression, this novel agent showed to be effective and safe
in patients with newly diagnosed MM. In particular, the
combination Rd proved to be a good induction treatment in
this setting of patients.
Based on the promising results achieved with Rd, ongo-
ing trials are now testing this regimen in combination with
other agents upfront with the aim to increase the tumoricidal
effect. Preliminary results showed the positive role of Rd in
association with clarithromycin, bortezomib, adriamycin or
cyclophosphamide.
In addition, studies are under way to assess the role
of long-term treatment with lenalidomide as consolida-
tion/maintenance treatment after ASCT, but longer followup
is necessary to draw any definitive conclusion.
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